SOX2 and cancer: Given that a key mechanism of drug resistance relates to the incapacity of most standard therapeutics to eradicate the minor subpopulation of CSC with self-renewal and seeding capacity, SOX2 has been suggested as an attractive anti-cancer target to prevent CSC-mediated clinical relapse [7, 8].